NCT01690533View on ClinicalTrials.gov

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

CompletedOBSERVATIONAL
Enrollment

497

Participants

Timeline

Start Date

May 13, 2008

Primary Completion Date

December 14, 2010

Study Completion Date

July 19, 2013

Conditions
Anti-Infective Agents
Interventions
DRUG

Avelox (Moxifloxacin, BAY12-8039)

Patients treated with Moxifloxacin in daily clinical practice

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01690533 - Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease | Biotech Hunter | Biotech Hunter